8 results about "Intracellular pathogen" patented technology

Mismatch anchoring compounds (MACs) are disclosed that recognize and bind to specific base-pair mismatches (mmBP) present within single stranded or double stranded DNA, RNA, and oligonucleotide sequences, and enable the ex vivo identification of DNA / RNA point mutations (DNAPM / RNAPM), including disease-associated, rare, and low abundance DNAPM / RNAPM, and the isolation and elimination of mmBP-positive cells. The use of MACs in vitro and in vivo (a) blocks mmBP-positive DNA replication and gene transcription / expression, (b) inhibits mmBP-positive cell proliferation, (c) reverses, prevents, and / or treats mmBP-rnediated disease, aging, and age-related disorders, (d) blocks mmBP-positive RNA and / or RNA-DNA duplex translation and inhibits the production of abnormal disease-causing proteins, (e) silence mmBP-positive genes, and (f) blocks intracellular pathogen replication. MAC-conjugates and their uses are disclosed, including MACs radiolabeled with SPECT / PET / particle-emitting isotopes for radioimaging and / or radiotherapy of mmBP-positive diseases.

A method of treating a patient with a tumor, and kits (200) for such treatment. The method includes administering, to the patient, a substance (204) which activates cytoplasmatic sensors for intracellular pathogen in the tumor and treating the tumor with intra-tumoral alpha-emitter radiotherapy within two weeks of administering the substance which activates cytoplasmatic sensors for intracellular pathogen in the tumor.

The application provides a supramolecular complex and a preparation method and application thereof, and belongs to the field of biological medicines. The supramolecular complex is prepared from raw materials in the following mass ratio: the mass ratio of puerarin to collagen or a complex thereof is 1:(0.5-20), or the mass ratio of an antibacterial peptide, puerarin and collagen or a complex thereof is 1:5:(2.5-100); the supramolecular complex can form a hydrogel. The supramolecular complex and the hydrogel thereof have significantly improved permeability, can effectively penetrate deep tissue and cells of gingival epithelium, deliver drugs into inner layers of tissue and cells, realize efficient clearance of intracellular pathogens, and break through the problem of insufficient clearance of intracellular bacteria in the existing periodontal drug delivery system. Meanwhile, the supramolecular complex has excellent antibacterial and anti-inflammatory properties and bone formation promoting ability, can effectively treat periodontitis, and provides a new integrated solution for periodontitis treatment.

Mismatch anchoring compounds (MACs) are disclosed that recognize and bind to specific base-pair mismatches (mmBP) present within single stranded or double stranded DNA, RNA, and oligonucleotide sequences, and enable the ex vivo identification of DNA / RNA point mutations (DNAPM / RNAPM), including disease-associated, rare, and low abundance DNAPM / RNAPM, and the isolation and elimination of mmBP-positive cells. The use of MACs in vitro and in vivo (a) blocks mmBP-positive DNA replication and gene transcription / expression, (b) inhibits mmBP-positive cell proliferation, (c) reverses, prevents, and / or treats mmBP-rnediated disease, aging, and age-related disorders, (d) blocks mmBP-positive RNA and / or RNA-DNA duplex translation and inhibits the production of abnormal disease-causing proteins, (e) silence mmBP-positive genes, and (f) blocks intracellular pathogen replication. MAC-conjugates and their uses are disclosed, including MACs radiolabeled with SPECT / PET / particle-emitting isotopes for radioimaging and / or radiotherapy of mmBP-positive diseases.

Described are novel antagonistic antibody molecules that specifically bind to TNFR2 on a target cell and thereby block TNF-α binding to TNFR2 and block TNFR2 signaling, wherein the antibody molecules also bind to Fc receptors via the Fc region. Also described is the use of such antibody molecules in treatment of cancer or infections caused by intracellular pathogens.

The invention discloses a cryptosporidium infection resisting medicine based on an APBB1 agonist and application of the cryptosporidium infection resisting medicine. Relates to application of APBB1 as a drug target protein in preparation of cryptosporidium infection resistant drugs, and a small molecule agonist 1-(4-((7-bromoquininolin-4-yl) amine) pheyl) ethan-1-one (named as' BP-5 ') capable of specifically up-regulating expression or activity of APBB1. The compound can enhance autophagy flow of host cells through pharmacological means and reverse autophagosome-lysosome fusion blocking caused by cryptosporidium effector protein CpCML, so that the autophagy flow of the host cells is recovered, the inherent defense function of parasitism of cryptosporidium in the cells is eliminated through the autophagy effect, and the treatment purpose is achieved. A new host-oriented treatment mechanism taking APBB1 as a target protein is proposed and verified for the first time, in-vitro experiments prove that the compound can remarkably reduce the number of cryptosporidium infection, the action mechanism is clear, drug resistance is not likely to be induced, and the compound has good clinical application prospects. A brand new path and a core technical scheme are provided for developing a novel medicine for resisting cryptosporidium infection and even other similar intracellular pathogen infection.

A vaccine composition comprising a virus antigen wherein the composition comprises less than 5% serum, wherein the virus antigen is a whole virus or derived from a whole virus, the vaccine composition reduces, prevents or avoids cross-stitch spinal deformity in the treated animal. Said vaccine composition for use in a method of treating a disease caused by the intracellular pathogen in an animal and reducing, preventing or avoiding cross-stitch spinal deformity in the treated animal. In cross-stitch vertebra the intervertebral space is completely collapsed. A vaccine composition for use as defined above wherein the animal is a fish. In an embodiment the pathogen is salmon alpha virus (SAV).

Methods for treating or preventing a chronic inflammatory diseases in an individual which includes administering a therapeutically effective amount of an inhibitor to the individual, wherein the inhibitor reduces or prevents intracellular pathogen formation or activity of a drug-resistant biofilm-associated pathogen, thereby treating or preventing the chronic inflammatory disease resulting from the intracellular pathogen or drug-resistant biofilm-associated pathogen. Examples include the chronic inflammatory disease atherosclerosis and the intracellular pathogen Porphyromonas gingivalis internalized in primary human coronary endothelial cells. Methods used to screen for inhibitor(s) of the intracellular pathogen formation or activity or formation or activity of a drug-resistant biofilm-associated pathogen are also included.